• Aslıhan Gürün Kaya, Aydın Çiledağ, Serhat Erol, Miraç Öz, Deniz Doğan Mülazımoğlu, Özlem Işık, Hilal Özakıncı, Fatma Çiftçi, Elif Şen, Koray Ceyhan, Akın Kaya, Demet Karnak, Gökhan Çelik, and Savaş İsmail.
• Department of Chest Diseases, 63990Ankara University Faculty of Medicine, Ankara, Turkey.
• Scot Med J. 2022 Feb 1; 67 (1): 18-27.

BackgroundGuidelines recommend performing biomarker tests for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF and ROS proto-oncogene-1(ROS1) genes and protein expression of programmed death ligand-1(PD-L1) in patients with non-small lung cell carcinoma (NSCLC). Studies reported that endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) can provide sufficient material for cancer biomarker analyses, but there are still concerns about the subject.AimThe purpose of the study was to assess the adequacy of EBUS-TBNA for testing lung cancer biomarkers.MethodsWe retrospectively reviewed patients with NSCLC whose EBUS-TBNA was analysed for EGFR, ALK, ROS-1, BRAF and PD-L1 expression between December 2011 and December 2020.ResultsA total of 394 patients were enrolled in the study. EGFR mutation and ALK fusion were the most common studied biomarkers. EBUS-TBNA adequacy rate for biomarker tests was found 99.0% for EGFR, 99.1 for ALK, 97.2% for ROS1, 100% for BRAF and 99.3% for PD-L1 testing. Multivariate analysis revealed the histological type, history of treatment for NSCL, size, or 18-fluorodeoxyglucose uptake of sampled lesion did not show any association with TBNA adequacy for biomarker testing.ConclusionEBUS-TBNA can provide adequate material for biomarker testing for EGFR, ALK, ROS-1, BRAF and PD-L1 expression.

30 keywords...

hide…